The pathophysiological role of cholecystokinin‐1 receptor in mouse cholelithogenesis

In November 2016, the Council of the European Society of Clinical Investigation (ESCI) evaluated all basic research articles published in European Journal of Clinical Investigation (EJCI) from November 2015 to October 2016. In the final selection round, four outstanding articles were selected based on their scientific impact, quality and novelty [1-4]. Among those high-quality finalists, the article by Wang and co-workers obtained the highest consideration by the ESCI Committee and was selected as the winner of the 2017 ESCI Award for the Best Basic Research Article [1]. In this animal study, inbred C57BL/6J mice were fed with normal chow or lithogenic diet for 21 days. Mice were then randomized to receive the cholecystokinin-1 receptor (CCK-1R) antagonist devazepide [(3S)(2)N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-yl)-1Hindole-2-carboxamide] at 4 mg/day/kg body weight twice per day. This article is protected by copyright. All rights reserved